Compare Advanced Micro Devices (AMD) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Biogen Inc — how do they compare? Advanced Micro Devices trades at $476.5 (market cap $766.54B), while Biogen Inc trades at $204.1 (market cap $30.60B). The key difference: Advanced Micro Devices is far larger — about 25.1× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Advanced Micro Devices nearer its low. Which is the better fit depends on your goals.
| AMD | BIIB | |
|---|---|---|
Market Cap | $766.54B | $30.60B |
Sector | Technology | Health |
52-Week High | $580.91 | $216.63 |
52-Week Low | $151.14 | $128.93 |
Enterprise Value | $757.71B | $37.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.
AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
